Synchron Completes Patient Enrollment in COMMAND Early Feasibility Study for Synchron Switch™ BCI System

On September 5, brain-computer interface company Synchron announced that“COMMAND”ofBrain-Computer InterfaceOral TestPatient recruitment for the Early Feasibility Study (EFS) has been completed.

According to Synchron, Inc., the COMMAND Early Feasibility Study enrolled a total of six patients and was conducted under the FDA’s Investigational Device Exemption (IDE) regulations. The study aimed to evaluate the safety of the Synchron Switch motor neuroprosthesis in patients with severe paralysis, while also assessing its quantitative efficacy.

The brain-computer interface trial, named “COMMAND,” commenced on March 20 this year. At that time, the brain-computer interface company Synchron announced that it would soon begin recruiting patients at the Gates Vascular Institute for the “COMMAND” brain-computer interface trial to test the feasibility of the Synchron Switch™ brain-computer interface device.

The primary objective of this study is to investigate whether the device can be safely implanted into the cerebral vasculature via endovascular neurosurgery. For patients who have lost the use of both hands, the study also aims to evaluate how brain-computer interfaces (BCIs) enable them to control digital devices through thought alone to perform daily tasks, such as sending text messages, emailing, online shopping, and accessing telehealth services.

Raul Nogueira, M.D., Professor of Neurology and Neurosurgery at the University of Pittsburgh, stated at Synchron’s press conference:“Allowing patients to choose brain-computer interface devices without the need for craniotomy may open up new frontiers in brain-computer interfaces.”We look forward to analyzing the study results and potentially bringing this technology to those in need in the future.”